Now Sun Pharma, Lupin work on anti-obesity pill to cut costs, address jab aversion
Both companies presented their plans to the Drug Supervisor of India (DCGI) by searching for regulatory approval to continue. Currently, wegovy, which is available as a pill and injection of Novo Nordisk’s pills and injection of Novo Nordisk, limits accessibility and patient comfort.
Although there is no data comparing the effectiveness of oral and injected semagludid variants, experts believe that the injectable form is more effective for weight loss, because it provides higher doses and is completely absorbed.
The queries sent to Sun Pharma, Lupine and the Ministry of Health remained unanswered until the press time.
The Specialist Committee of the Indian Drug Inspector (DCGI) has allowed Sun Pharma for a large -scale clinical study to test the Semagluid tablets.
Lupine also received green light for Bioqualness (BE), which aims to prove that the generic drug works the same as the original branded version.
Considering that obesity has become a public health difficulty in India, it is a Lancet work that predicts that India may have 450 million overweight and obese adults by 2050.
Regulatory push
DCGI’s Specialist Committee (SEC) gave Sun Pharma Cleans for Semaglidid tablets to start a clinical work. In the meantime, the lupin is allowed to perform a bioequisal value that will show that the general version of the general version is performing similarly to the original drug. Be operation will test the powerful aspects of 3 mg, 7 mg and 14 mg.
SPARSH GROUP HOSPITAL PRESIDENT Sharan Shivaraj Patil, “Today, greater concern is obesity that has become a quiet but serious threat to public health. India is going in the same direction.” He said. Obesity worsens every medical condition – from arthritis and diabetes to surgery complications. “No matter how early we accept obesity as a national challenge and take steps to address it, our nation will be healthier.
Other Indian companies are also in the field to develop injections, especially to develop injections, and after the end of the patents, they are preparing to start the general versions of Semagludidine.
Dr. Other Indian pharmaceutical companies such as Reddy’s Laboratoies LTD and Jepla LTD are actively developing Semagludidine generic versions. Humanity Pharma is also working on Semagluid generic. Biocon is another company that receives approval for Liraglid injection, which is the complex formulation used for weight management.
Dean of the Holy Family Hospital and General Manager of Indian Medical Research Council (ICMR) According to Balram Bhargava, “these are rightly called ‘magic for obesity’ and new inventions.
Generic
Dr. Although Bhargava also has some side effects, he said, ‘They are not so worrying’. The irrational use of these drugs may have serious consequences. “These drugs mimic a natural body hormone and their use should definitely be arranged,” he said. They are obese and diabetic, but are suitable as a second treatment line for individuals who should not be used by “lean and thin people”.
Former ICMR DG, until next year there may be a generic version flood in the market, he added. “If we have a strong national regulatory system, then we will do it very well as a nation.” It should be seen that these anti-bezity drugs are used in India, how practitioners and patients accept them, and most importantly, they ensure that they are not abused. Incurrent use, the drug can lead to stigmatization, he said.
Lock Inferences
1. Sun Pharma and Lupine develop oral Semaglidid pills for obesity and avoidance of injection.
2. Phase III trials (Sun) and Be studies (lupine) are given regulatory approvals.
3. India faces 450 million adult obesity burden by 2050.
4. Experts draw attention to strict medical control and abuse.
5. Generic versions can float on the market next year and reshape affordable price and access.
